Cargando…
Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create opportunities to reduce CM treatment costs compare...
Autores principales: | Larson, Bruce, Shroufi, Amir, Muthoga, Charles, Oladele, Rita, Rajasingham, Radha, Jordan, Alexander, Jarvis, Joseph N., Chiller, Tom M., Govender, Nelesh P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184925/ https://www.ncbi.nlm.nih.gov/pubmed/35706922 http://dx.doi.org/10.12688/wellcomeopenres.16776.3 |
Ejemplares similares
-
Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana
por: Tenforde, Mark W., et al.
Publicado: (2020) -
Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda
por: Ramachandran, Anu, et al.
Publicado: (2017) -
Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis
por: Rajasingham, Radha, et al.
Publicado: (2012) -
Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/µL in Botswana
por: Tenforde, Mark W., et al.
Publicado: (2021) -
Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis
por: Rajasingham, Radha, et al.
Publicado: (2019)